NO973470L - Fremgangsmåte for minsking av serumkalsiumnivåer - Google Patents
Fremgangsmåte for minsking av serumkalsiumnivåerInfo
- Publication number
- NO973470L NO973470L NO973470A NO973470A NO973470L NO 973470 L NO973470 L NO 973470L NO 973470 A NO973470 A NO 973470A NO 973470 A NO973470 A NO 973470A NO 973470 L NO973470 L NO 973470L
- Authority
- NO
- Norway
- Prior art keywords
- calcium levels
- serum calcium
- procedure
- reducing serum
- hexamethylimino
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract 2
- 229910052791 calcium Inorganic materials 0.000 title abstract 2
- 239000011575 calcium Substances 0.000 title abstract 2
- 210000002966 serum Anatomy 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Liquid Crystal Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pyrrole Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Fremgangsmåte for minsking av serumkalsiumnivåer Fremgangsmåte for senking av serumkalsiumnivåer omfattende administrasjon til et menneske som har behov for dette av en effektiv mengde av en forbindelse som har formelen: OCH2CH2¿R^ (I) O 0 hvor r' og r3 uavhengig er hydrogen, -CH3, -C-(Ci-C6 alkyl), eller -C-Ar, hvor Ar er eventuelt substituert fenyl; r2 er valgt fra gruppen bestående av pyrrolidin, heksametylimino og piperidino; eller et farmasøytisk akseptabelt salt eller solvat derav.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/380,881 US5512583A (en) | 1995-01-30 | 1995-01-30 | Methods of decreasing serum calcium levels |
PCT/US1996/001406 WO1996023501A1 (en) | 1995-01-30 | 1996-01-29 | Methods of decreasing serum calcium levels |
Publications (2)
Publication Number | Publication Date |
---|---|
NO973470L true NO973470L (no) | 1997-07-28 |
NO973470D0 NO973470D0 (no) | 1997-07-28 |
Family
ID=23502813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO973470A NO973470D0 (no) | 1995-01-30 | 1997-07-28 | Fremgangsmåte for minsking av serumkalsiumnivåer |
Country Status (19)
Country | Link |
---|---|
US (1) | US5512583A (no) |
EP (1) | EP0723780B1 (no) |
JP (1) | JPH10513184A (no) |
KR (1) | KR19980701731A (no) |
CN (1) | CN1086943C (no) |
AT (1) | ATE216232T1 (no) |
AU (1) | AU701262B2 (no) |
CA (1) | CA2211530A1 (no) |
CZ (1) | CZ286161B6 (no) |
DE (1) | DE69620661T2 (no) |
DK (1) | DK0723780T3 (no) |
ES (1) | ES2172633T3 (no) |
HU (1) | HUP9801335A3 (no) |
NO (1) | NO973470D0 (no) |
NZ (1) | NZ302546A (no) |
PT (1) | PT723780E (no) |
RU (1) | RU2176503C2 (no) |
UA (1) | UA43389C2 (no) |
WO (1) | WO1996023501A1 (no) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
DE4320896A1 (de) * | 1993-06-24 | 1995-01-05 | Denecke Rainer Dr Med Vet | Präparat zur Therapie und Prophylaxe von Demenz-Erkrankungen |
US5478847A (en) * | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
PL181304B1 (pl) * | 1994-07-22 | 2001-07-31 | Lilly Co Eli | Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL |
-
1995
- 1995-01-30 US US08/380,881 patent/US5512583A/en not_active Expired - Fee Related
-
1996
- 1996-01-29 JP JP8523733A patent/JPH10513184A/ja not_active Withdrawn
- 1996-01-29 HU HU9801335A patent/HUP9801335A3/hu unknown
- 1996-01-29 WO PCT/US1996/001406 patent/WO1996023501A1/en not_active Application Discontinuation
- 1996-01-29 AT AT96300610T patent/ATE216232T1/de not_active IP Right Cessation
- 1996-01-29 RU RU97114794/14A patent/RU2176503C2/ru active
- 1996-01-29 NZ NZ302546A patent/NZ302546A/en unknown
- 1996-01-29 AU AU48622/96A patent/AU701262B2/en not_active Ceased
- 1996-01-29 EP EP96300610A patent/EP0723780B1/en not_active Expired - Lifetime
- 1996-01-29 UA UA97074027A patent/UA43389C2/uk unknown
- 1996-01-29 PT PT96300610T patent/PT723780E/pt unknown
- 1996-01-29 DE DE69620661T patent/DE69620661T2/de not_active Expired - Fee Related
- 1996-01-29 CZ CZ19972403A patent/CZ286161B6/cs not_active IP Right Cessation
- 1996-01-29 ES ES96300610T patent/ES2172633T3/es not_active Expired - Lifetime
- 1996-01-29 DK DK96300610T patent/DK0723780T3/da active
- 1996-01-29 CN CN96191671A patent/CN1086943C/zh not_active Expired - Fee Related
- 1996-01-29 CA CA002211530A patent/CA2211530A1/en not_active Abandoned
- 1996-01-29 KR KR1019970705127A patent/KR19980701731A/ko not_active Application Discontinuation
-
1997
- 1997-07-28 NO NO973470A patent/NO973470D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CZ240397A3 (cs) | 1998-01-14 |
RU2176503C2 (ru) | 2001-12-10 |
KR19980701731A (ko) | 1998-06-25 |
CA2211530A1 (en) | 1996-08-08 |
MX9705697A (es) | 1997-10-31 |
NZ302546A (en) | 2000-06-23 |
AU701262B2 (en) | 1999-01-21 |
WO1996023501A1 (en) | 1996-08-08 |
CZ286161B6 (cs) | 2000-01-12 |
EP0723780B1 (en) | 2002-04-17 |
AU4862296A (en) | 1996-08-21 |
HUP9801335A2 (hu) | 1999-05-28 |
US5512583A (en) | 1996-04-30 |
DE69620661D1 (de) | 2002-05-23 |
ES2172633T3 (es) | 2002-10-01 |
DK0723780T3 (da) | 2002-06-17 |
DE69620661T2 (de) | 2002-11-14 |
JPH10513184A (ja) | 1998-12-15 |
HUP9801335A3 (en) | 2000-03-28 |
PT723780E (pt) | 2002-08-30 |
EP0723780A3 (no) | 1996-09-11 |
ATE216232T1 (de) | 2002-05-15 |
EP0723780A2 (en) | 1996-07-31 |
CN1086943C (zh) | 2002-07-03 |
UA43389C2 (uk) | 2001-12-17 |
CN1172432A (zh) | 1998-02-04 |
NO973470D0 (no) | 1997-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY132056A (en) | Methods of inhibiting physiological conditions associated with an excess of neuropeptide y. | |
MY132251A (en) | Methods of inhibiting cell-cell adhesion | |
NO944911L (no) | Ikke-peptid-takykininreseptorantagonister | |
NO944919L (no) | Fremgangsmåte for å inhibere atrofi av huden eller vagina | |
NO944914L (no) | Fremgangsmåte for å inhibere autoimmunsykdommer | |
DK0652005T3 (da) | Fremgangsmåder til inhibering af endometriose | |
NO944927L (no) | Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom | |
NO944930L (no) | Hemming av dysfunksjonell uterin blödning | |
NO944934L (no) | Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom | |
MX9701325A (es) | Metodos para inhibir la mucositis ulcerativa. | |
ES2141957T3 (es) | Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales. | |
UA32427C2 (uk) | Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань | |
NO944926L (no) | Fremgangsmåter for å inhibere myeloperoksidaseaktivitet | |
NO944924L (no) | Fremgangsmåter for inhibering av Turner's syndrom | |
NO944933L (no) | Fremgangsmåte for å inhibere sykdomstilstander i brystet | |
NO944917L (no) | Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av ovarial dysgenese, forsinket pubertet eller seksuell infantilisme | |
NO970786L (no) | Fremgangsmåte for hemming av benprotesedegradering | |
NO975580L (no) | Fremgangsmåte for å inhibere melanom | |
NO973367L (no) | Fremgangsmåte for å inhibere miljömessige östrogen | |
NO981578L (no) | FremgangsmÕte for hemming av plasminogenaktivatorhemmer I | |
NO973470L (no) | Fremgangsmåte for minsking av serumkalsiumnivåer | |
NO944577L (no) | Hemming av effekten av amyloidogene proteiner | |
NO973103L (no) | Fremgangsmåte for inhibering av veksthormoneffekter | |
NO973609L (no) | Fremgangsmåte for å inhibere effektene av IL-6 | |
NO944910L (no) | Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |